New KRAS Inhibitor Shows Promise in NSCLC New KRAS Inhibitor Shows Promise in NSCLC

The KRAS (G12C) inhibitor adagrasib induced an objective response in about one out of three patients with previously treated KRAS (G12C) –mutated non–small cell lung cancer (NSCLC).Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news